Document is current

Article History

Received: 25 March 2025

Accepted: 8 May 2025

First Online: 2 June 2025

Declarations

:

: Not applicable.

: Not applicable.

: CMV has received speaker and consultancy fees from Chiesi Pharmaceuticals, PTC Therapeutics, Lilly, Merck, BI-Lilly and Novo Nordisk, was principal investigator on a Chiesi clinical trial and was sponsored from Novo Nordisk, Lilly, Chiesi and PTC for participation in conferences. LFV reports receiving payment or honoraria from Novo Nordisk and AstraZeneca and has received travel and meeting support from Novo Nordisk, Eli Lilly and Company, PTC Therapeutics, and Chiesi. NGR has received speaker and consultancy fees from Chiesi Pharmaceuticals. And PTC Therapeutics, speaker honorarium from BI-Lilly and Novo Nordisk and was sponsored from Novo Nordisk, Lilly, PTC Therapeutics, Takeda and Merck for participation in conferences. JL has received speaker and consultancy fees from NovoNordisk, Abbott and Chiesi. AFG-M has received speaker and consultancy fees from Astra-Zeneca, Lilly, NovoNordisk, PTC Therapeutics, and Takeda, and was sponsored from Astra-Zeneca, Novo Nordisk, Lilly and Takeda for participation in conferences. AH reports receiving consulting fees from Besins, Brace Pharma, Daiichi Sankyo, Lilly, Merck and Novo Nordisk. FRT declare that received fees from the following companies for lectures and consultancy: Aché, AstraZeneca, BracePharma, Boehringer Ingelheim and Eli Lilly do Brasil, EMS, Eurofarma, Johnson & Johnson, Myrallis, Merck, Novo Nordisk, Servier, Scitech Medical, Takeda. JTAMC has received speaker fees from Chiesi Pharmaceuticals. JRD has received speaker fees from Chiesi, Merck, Astra-Zeneca and NovoNordisk, consultancy fees from Novartis and was sponsored from Astra-Zeneca and Novo Nordisk for participation in conferences. LZ has received speaker fees from NovoNordisk and Chiesi Pharmaceuticals and sponsored from Novo Nordisk, for participation in conferences. RBGM has no conflits of interest for this manuscript. ROM has received speaker fees from Astra-Zeneca, Merck, Bayer, Libbs, EMC, Brace Pharma, Servier, PTC, Lilly and NovoNordisk, consultancy fees from NovoNordisk, AstraZeneca, Viatris, Bayer, Merck and was sponsored from Astra-Zeneca, Bayer and Novo Nordisk for participation in conferences. VOF has received speaker fees or participated in clinical studies as SI of Chiesi, PTC and Boehringer Ingelheim. MCFF has no conflits of interest for this manuscript. RMMJ has received speaker fees, consultant fees or participate in clinical studies as PI of Chiesi, PTC, Hypera, Astrazeneca, Sanofi, Servier, Eli Lilly, and Novo Nordisk.